123690-78-8
123690-78-8
Chemical Structure
CGP 36742
Synonym(s): SGS-742
- CAS. Nr.: 123690-78-8
- Formula:C7H18NO2P
- Molecular Weight:179.20
IUPAC Name: (3-aminopropyl)(butyl)phosphinic acid
InChIKey: ONNMDRQRSGKZCN-UHFFFAOYSA-N
SMILES: O=P(CCCN)(O)CCCC
Biological Activity: CGP 36742 (SGS-742) is an orally active and selective antagonist of GABAB receptor (IC50 = 36 µM). CGP 36742 is a brain-penetrant compound and improves cognitive performances. CGP 36742 can be used for depression study[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CGP 36742 | 98.0% | CGP 36742 (SGS-742) is an orally active and selective antagonist of GABAB receptor (IC50 = 36 µM). CGP 36742 is a brain-penetrant compound and improves cognitive performances. CGP 36742 can be used for depression study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CGP 36742 (Standard) | ≥98% | CGP 36742 (Standard) is the analytical standard of CGP 36742. This product is intended for research and analytical applications. CGP 36742 (SGS-742) is an orally active and selective antagonist of GABAB receptor (IC50 = 36 µM). CGP 36742 is a brain-penetrant compound and improves cognitive performances. CGP 36742 can be used for depression study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nowak G, et al. Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol. 2006 Nov;149(5):581-90. [Content Brief]
- [2]. Olpe HR, et al. The actions of orally active GABAB receptor antagonists on GABAergic transmission in vivo and in vitro. Eur J Pharmacol. 1993 Mar 23;233(2-3):179-86. [Content Brief]
- [3]. Andrén PE, et al. Blood-brain barrier penetration of 3-aminopropyl-n-butylphosphinic acid (CGP 36742) in rat brain by microdialysis/mass spectrometry. J Mass Spectrom. 1998 Mar;33(3):281-7. [Content Brief]
- [4]. Pittaluga A, et al. Potentiation of NMDA receptor function through somatostatin release: a possible mechanism for the cognition-enhancing activity of GABA(B) receptor antagonists. Neuropharmacology. 2001 Sep;41(3):301-10. [Content Brief]
